查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1456961

全球抗體藥物複合體市場：2024年至2029年預測

Global Antibody Drug Conjugates Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 210 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

抗體藥物複合體市場預計將從 2022 年的 70.17 億美元增至 2029 年的 388.85 億美元，預測期內複合年成長率為 27.7%。

抗體藥物複合體（簡稱 ADC）是設計用於癌症治療的標靶治療的生物藥品。抗體藥物複合體將單株抗體的特異性標靶特性與細胞毒性藥物的抗癌能力結合起來，能夠靈敏地區分健康組織和患病組織。 ADC 是三組分系統，其中有效的細胞毒性抗癌藥物透過生物分解性的接頭連接到抗體上。抗體與癌細胞表面的特定標記（抗原或受體）結合。在癌細胞內部，整個抗體-藥物綴合物被內化，連接體被分解，釋放出活性藥物。

推動抗體藥物複合體市場的主要成長要素是癌症盛行率的增加。癌症每年影響數百萬人的生命，而且這個數字還在持續上升。開發有效治療方法的需求從未如此迫切。此外，提高個人健康意識有助於及早發現癌症，以便及時治療，避免癌症進一步擴散到身體其他部位。此外，增加癌症治療的醫療保健支出以及增加 ADC 的研發在全球抗體藥物複合體市場的成長中發揮著重要作用。此外，標靶化癌症治療的全球趨勢以及 ADC 研發的活性化也對市場做出了重大貢獻。標靶治療有助於消除癌細胞，而不會真正傷害健康細胞。

市場驅動力

  • 癌症患者增加

癌症患者的數量正在增加。癌症是全球第二大死因。根據世界衛生組織（WHO）估計，2018年全球將有960萬人死於癌症。每年約有 40 萬名兒童罹患癌症。人們對癌症的認知不斷提高以及醫療機構的早期發現使得在癌症造成嚴重損害之前將其消滅成為可能。久坐的生活方式以及垃圾食物、菸草和酒精的消費量增加是導致癌症的常見因素。大約三分之一的死亡是由吸煙和飲酒、肥胖、水果和蔬菜攝入量低以及缺乏運動造成的。 2020年，最常見的死因是肺癌，其次是大腸癌和肝癌。肺癌造成 1.8 億人死亡，大腸癌造成 9,350 人死亡，肝癌造成 83 萬人死亡。乳癌也是最常見的癌症之一。早期發現和適當的治療可以預防死亡。目前，30-50%的癌症患者是可以預防的。

  • ADC 研究和開發在世界各地變得越來越廣泛。

隨著各公司加強研發力度以尋找有效的癌症治療方法，越來越多的公司正在投資研發來開發此類藥物。隨著認知的深入和新技術的出現，ADC研發的範圍正在進一步擴大。此外，美國食品藥物管理局（FDA）產品的核准率顯著提高。 2021年，已有12個ADC藥物核准。此外，正在深入研究 ADC 和免疫系統之間的相互作用，以尋找可能的協同治療效果，從而可用於藥物改進。

市場限制因素

  • 昂貴的治療費用

癌症治療需要花很多錢。這是由於該藥物需要大量的研究、許可、專利和製造成本。根據世界衛生組織 (WHO) 統計，2010 年癌症造成的年度經濟損失估計為 1.16 兆美元。抗體藥物複合體對於癌症患者來說是昂貴的治療方法，而用於研究和開發的時間和金錢也增加了成本。 ADC 的製造成本也較高，這會增加到最終模具中。原料成本在製造過程中占主導地位。根據毒素的性質，藥物粘合劑的原料價格在每克 200 美元到 2,000 美元之間。此外，如果每年只生產少量劑量，就無法實現規模經濟。此外，藥品監管部門的嚴格監管也推高了成本。

主要進展

  • 2023年7月－ImmunoBiochem與ImmunoGen簽訂了多標靶許可和選擇權協議，以推進抗體藥物複合體（ADC）的開發。此次合作將ImmunoGen 的接頭和有效負載技術與ImmunoBiochem 的目標特異性抗體結合。免疫生物化學公司收到預付款，以換取現有抗體的獨家許可。
  • 2023年7月——百濟神州和 DualityBio 達成協議，獲得針對固體癌患者的臨床前 ADC 療法的全球臨床和商業許可的獨家選擇權。 DualityBio 將收到預付款和基於里程碑的額外付款，總合高達 13 億美元。百濟神州持有全球權利，而 DualityBio 將進行研究並支持未來的 IND 申請。

目錄

第1章 簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現
  • CXO觀點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球抗體藥物複合體市場：依產品類型

  • 介紹
  • ADCETRIS
    • 市場機會和趨勢
    • 成長前景
    • 地理收益
  • 門頭
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利

第6章全球抗體藥物複合體市場：以標靶類型

  • 介紹
  • CD30抗體
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • Her2抗體
    • 市場機會趨勢
    • 成長前景
    • 地域盈利
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利

第7章抗體藥物複合體的全球市場：依技術分類

  • 介紹
  • 可切割接頭
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • 不可切割的接頭
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利

第8章抗體藥物複合體的全球市場：按應用

  • 介紹
  • 乳癌
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • 血癌
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • 泌尿道癌/膀胱癌
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • 子宮頸癌和頭頸癌
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利

第9章全球抗體藥物複合體市場：依最終用戶分類

  • 介紹
  • 醫院
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • 診所
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • 其他
    • 市場機會趨勢
    • 成長前景
    • 地理收益

第10章全球抗體藥物複合體市場：按地區

  • 介紹
  • 北美洲
    • 依產品類型
    • 按目標類型
    • 依技術
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 南美洲
    • 依產品類型
    • 按目標類型
    • 依技術
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 歐洲
    • 依產品類型
    • 按目標類型
    • 依技術
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 中東/非洲
    • 依產品類型
    • 按目標類型
    • 依技術
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 亞太地區
    • 依產品類型
    • 按目標類型
    • 依技術
    • 按用途
    • 按最終用戶
    • 按國家/地區

第11章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第12章 公司簡介

  • The Linde Group
  • Astrazeneca
  • Pfizer, Inc
  • Seagen, Inc.
  • GSK Plc
  • Takeda Pharmaceutical Company Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Novartis
  • Gilead Sciences, Inc.
  • Sanofi SA
  • Astellas Pharma
  • Daiichi Sankyo Company Ltd.
  • Genentech Inc.
  • Immunogen Inc.
  • Lantheus
  • Bayer Healthcare Pharmaceuticals
  • Astellas Pharma
  • Synthon Holding BV
簡介目錄
Product Code: KSI061612249

The global antibody drug conjugates market is projected to witness a CAGR of 27.7% during the forecast period to reach a total market size of US$38.885 billion by 2029, increasing from US$7.017 billion in 2022.

Antibody Drug Conjugates, or ADCs for short, are biological drugs designed as a targeted therapy for treating cancer. Antibody-drug conjugates provide sensitive differentiation between healthy and diseased tissue by combining the specific targeting of monoclonal antibodies with the cancer-killing capacity of cytotoxic medicines. ADC is a three-component system with a potent cytotoxin anticancer agent linked by a biodegradable linker to an antibody. The antibody attaches to certain markers on the cancer cell's surface (antigens or receptors). Within the cancer cell, the entire antibody-drug conjugate is internalized, where the linker is degraded and the active drug is liberated.

The key growth factor driving the antibody-drug conjugate market is the growing prevalence of cancer. Cancer affects millions of lives every year and is increasing. The need to develop an effective treatment is higher than ever before. Further, increasing health consciousness amongst individuals helps identify cancer in its early stages, which can be treated on time without any further spread of cancer to other parts of the body. Moreover, growing healthcare expenditure on cancer treatment and rising R&D in ADCs play an important role in the growth of the global antibody-drug conjugate market. Furthermore, the global trend toward targeted cancer therapeutics, as well as increased research and development on ADCs, are significantly contributing to the market. Targeted therapy helps to eliminate cancer cells without actually harming healthy cells.

MARKET DRIVERS

  • Patients with Cancer Are Increasing

Patients with cancer have seen an upward trend. Globally, cancer is the second largest cause of death. According to the World Health Organization, 9.6 million people are estimated to die due to cancer worldwide in 2018. Around 400,000 children develop cancer each year. With increasing awareness of cancer and rising, medical facility detection of cancer in its early stages, early detections help eliminate it before some serious damage is done. An increasingly sedentary lifestyle and increasing consumption of junk food, tobacco, and alcohol are some of the prevalent factors causing cancer. Around one-third of deaths are from cancer due to tobacco and alcohol use, obesity, low fruit and vegetable intake, and lack of physical activity. In 2020, the most common cause of death was lung cancer, followed by colon and rectum cancer, and liver cancer. Accounting for 180 million deaths by lung cancer, 9.35 thousand deaths due to colon and rectal cancer, and 830 thousand deaths due to liver cancer. Breast cancer is another of the most common types of cancer. With early detection and proper treatment, deaths could be prevented. Between 30-50% of cancer cases can currently be prevented.

  • ADC research and development is becoming increasingly extensive around the world.

With the increasing development in research and development by various companies to find an effective cancer treatment, more and more companies are investing in R&D to develop such drugs. With a deeper understanding and the advent of new technology, the scope of R&D in ADCs has further increased. Moreover, the approval rate for U.S. Food and Drug Association (FDA) products has increased significantly. In the year 2021, 12 ADC drugs have been approved. Further, deep research on interactions between ADCs and the immune system for potential synergistic therapeutic effects that can be used to improve the drug is taking place.

MARKET RESTRAINT:

  • Expensive Treatment

Cancer treatments come with a hefty price tag., due to extensive research, licensing, patents, and manufacturing costs of drugs. According to the World Health Organization (WHO), the total annual economic cost of cancer in 2010 was estimated at US$ 1.16 trillion. Antibody-drug conjugates can be an expensive treatment for cancer patients, with a high level of time and money invested in R&D adding to the cost. ADCs also have a high manufacturing cost, which adds up to the final cast. The dominant cost in the manufacturing process of raw materials. Depending on the nature of the toxins, the drug-linker raw material can cost between $200-$2000 per gram. Furthermore, a small batch of doses produced per year is not able to reach economies of scale. Further, strict regulation from medical and drug authorities adds to the cost.

Key Developments:

  • July 2023- ImmunoBiochem has signed a multi-target license and option agreement with ImmunoGen to advance antibody-drug conjugates (ADCs). The collaboration will combine ImmunoGen's linker and payload technologies with ImmunoBiochem's antibodies against specific targets. ImmunoBiochem will receive an upfront fee in exchange for an exclusive license to existing antibodies. The collaboration will focus on preclinical activities, with ImmunoGen responsible for clinical development and commercialization.
  • July 2023- BeiGene and DualityBio have agreed to acquire an exclusive option for a global clinical and commercial license for an investigational, preclinical ADC therapy for patients with solid tumors. DualityBio will receive an upfront payment and additional payments based on milestones, totaling up to $1.3 billion. BeiGene will hold global rights, while DualityBio will conduct research and support future IND filings.

Market Segmentation:

By Product Type

  • Adcetris
  • Kadcyla
  • Other Product Types

By Target Type

  • Cd30 Antibodies
  • Her2 Antibodies
  • Others

By Technology

  • Cleavable Linker
  • Non-Cleavable Linker

By Application

  • Breast Cancer
  • Blood Cancer
  • Urinary Tract/Bladder Cancer
  • Cervical And Head & Neck Cancer

By End-User

  • Hospitals
  • Clinics
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Adcetris
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Kadcyla
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Others
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness

6. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE

  • 6.1. Introduction
  • 6.2. Cd30 Antibodies
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Her2 Antibodies
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Others
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY TECHNOLOGY

  • 7.1. Introduction
  • 7.2. Cleavable Linker
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Non-Cleavable Linker
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness

8. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION

  • 8.1. Introduction
  • 8.2. Breast Cancer
    • 8.2.1. Market Opportunities and Trends
    • 8.2.2. Growth Prospects
    • 8.2.3. Geographic Lucrativeness
  • 8.3. Blood Cancer
    • 8.3.1. Market Opportunities and Trends
    • 8.3.2. Growth Prospects
    • 8.3.3. Geographic Lucrativeness
  • 8.4. Urinary Tract/Bladder Cancer
    • 8.4.1. Market Opportunities and Trends
    • 8.4.2. Growth Prospects
    • 8.4.3. Geographic Lucrativeness
  • 8.5. Cervical And Head & Neck Cancer
    • 8.5.1. Market Opportunities and Trends
    • 8.5.2. Growth Prospects
    • 8.5.3. Geographic Lucrativeness

9. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY END-USER

  • 9.1. Introduction
  • 9.2. Hospitals
    • 9.2.1. Market Opportunities and Trends
    • 9.2.2. Growth Prospects
    • 9.2.3. Geographic Lucrativeness
  • 9.3. Clinics
    • 9.3.1. Market Opportunities and Trends
    • 9.3.2. Growth Prospects
    • 9.3.3. Geographic Lucrativeness
  • 9.4. Others
    • 9.4.1. Market Opportunities and Trends
    • 9.4.2. Growth Prospects
    • 9.4.3. Geographic Lucrativeness

10. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY GEOGRAPHY

  • 10.1. Introduction
  • 10.2. North America
    • 10.2.1. By Product Type
    • 10.2.2. By Target Type
    • 10.2.3. By Technology
    • 10.2.4. By Application
    • 10.2.5. By End-User
    • 10.2.6. By Country
      • 10.2.6.1. United States
        • 10.2.6.1.1. Market Opportunities and Trends
        • 10.2.6.1.2. Growth Prospects
      • 10.2.6.2. Canada
        • 10.2.6.2.1. Market Opportunities and Trends
        • 10.2.6.2.2. Growth Prospects
      • 10.2.6.3. Mexico
        • 10.2.6.3.1. Market Opportunities and Trends
        • 10.2.6.3.2. Growth Prospects
  • 10.3. South America
    • 10.3.1. By Product Type
    • 10.3.2. By Target Type
    • 10.3.3. By Technology
    • 10.3.4. By Application
    • 10.3.5. By End-User
    • 10.3.6. By Country
      • 10.3.6.1. Brazil
        • 10.3.6.1.1. Market Opportunities and Trends
        • 10.3.6.1.2. Growth Prospects
      • 10.3.6.2. Argentina
        • 10.3.6.2.1. Market Opportunities and Trends
        • 10.3.6.2.2. Growth Prospects
      • 10.3.6.3. Others
        • 10.3.6.3.1. Market Opportunities and Trends
        • 10.3.6.3.2. Growth Prospects
  • 10.4. Europe
    • 10.4.1. By Product Type
    • 10.4.2. By Target Type
    • 10.4.3. By Technology
    • 10.4.4. By Application
    • 10.4.5. By End-User
    • 10.4.6. By Country
      • 10.4.6.1. United Kingdom
        • 10.4.6.1.1. Market Opportunities and Trends
        • 10.4.6.1.2. Growth Prospects
      • 10.4.6.2. Germany
        • 10.4.6.2.1. Market Opportunities and Trends
        • 10.4.6.2.2. Growth Prospects
      • 10.4.6.3. France
        • 10.4.6.3.1. Market Opportunities and Trends
        • 10.4.6.3.2. Growth Prospects
      • 10.4.6.4. Italy
        • 10.4.6.4.1. Market Opportunities and Trends
        • 10.4.6.4.2. Growth Prospects
      • 10.4.6.5. Spain
        • 10.4.6.5.1. Market Opportunities and Trends
        • 10.4.6.5.2. Growth Prospects
      • 10.4.6.6. Others
        • 10.4.6.6.1. Market Opportunities and Trends
        • 10.4.6.6.2. Growth Prospects
  • 10.5. Middle East and Africa
    • 10.5.1. By Product Type
    • 10.5.2. By Target Type
    • 10.5.3. By Technology
    • 10.5.4. By Application
    • 10.5.5. By End-User
    • 10.5.6. By Country
      • 10.5.6.1. Saudi Arabia
        • 10.5.6.1.1. Market Opportunities and Trends
        • 10.5.6.1.2. Growth Prospects
      • 10.5.6.2. UAE
        • 10.5.6.2.1. Market Opportunities and Trends
        • 10.5.6.2.2. Growth Prospects
      • 10.5.6.3. Others
        • 10.5.6.3.1. Market Opportunities and Trends
        • 10.5.6.3.2. Growth Prospects
  • 10.6. Asia Pacific
    • 10.6.1. By Product Type
    • 10.6.2. By Target Type
    • 10.6.3. By Technology
    • 10.6.4. By Application
    • 10.6.5. By End-User
    • 10.6.6. By Country
      • 10.6.6.1. Japan
        • 10.6.6.1.1. Market Opportunities and Trends
        • 10.6.6.1.2. Growth Prospects
      • 10.6.6.2. China
        • 10.6.6.2.1. Market Opportunities and Trends
        • 10.6.6.2.2. Growth Prospects
      • 10.6.6.3. India
        • 10.6.6.3.1. Market Opportunities and Trends
        • 10.6.6.3.2. Growth Prospects
      • 10.6.6.4. South Korea
        • 10.6.6.4.1. Market Opportunities and Trends
        • 10.6.6.4.2. Growth Prospects
      • 10.6.6.5. Taiwan
        • 10.6.6.5.1. Market Opportunities and Trends
        • 10.6.6.5.2. Growth Prospects
      • 10.6.6.6. Thailand
        • 10.6.6.6.1. Market Opportunities and Trends
        • 10.6.6.6.2. Growth Prospects
      • 10.6.6.7. Indonesia
        • 10.6.6.7.1. Market Opportunities and Trends
        • 10.6.6.7.2. Growth Prospects
      • 10.6.6.8. Others
        • 10.6.6.8.1. Market Opportunities and Trends
        • 10.6.6.8.2. Growth Prospects

11. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 11.1. Major Players and Strategy Analysis
  • 11.2. Market Share Analysis
  • 11.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 11.4. Competitive Dashboard

12. COMPANY PROFILES

  • 12.1. The Linde Group
  • 12.2. Astrazeneca
  • 12.3. Pfizer, Inc
  • 12.4. Seagen, Inc.
  • 12.5. GSK Plc
  • 12.6. Takeda Pharmaceutical Company Ltd.
  • 12.7. F. Hoffmann-La Roche Ltd.
  • 12.8. Novartis
  • 12.9. Gilead Sciences, Inc.
  • 12.10. Sanofi S.A.
  • 12.11. Astellas Pharma
  • 12.12. Daiichi Sankyo Company Ltd.
  • 12.13. Genentech Inc.
  • 12.14. Immunogen Inc.
  • 12.15. Lantheus
  • 12.16. Bayer Healthcare Pharmaceuticals
  • 12.17. Astellas Pharma
  • 12.18. Synthon Holding BV